BRIEF — Drug-focused AI company raises $115 million

BenevolentAI, a UK artificial intelligence (AI) company focused on health and drug development, has raised $115 million in a financing.

The funding round was led by new and existing investors, mostly based in the USA, and is one of the largest to date in the growing AI pharma sector. It takes BenevolentAI’s fundraising more than $200 million since 2013.